Showing results (341-350 of 416) with videos related to
Sort By:
Pageof 42
Immunogenetics|June 15, 2023
Complement component C1q is an immunological rheostat that regulates Fc:Fc R interactionsEdward C So, Hua Zhou, Ariana Greenwell, et al.Gynecologic Oncology|July 13, 2023
Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis?Anousheh Shafa, A Brooke Watkins, Michaela E McGree, et al.Arthritis Research & Therapy|August 22, 2012
Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceAjay Jain, Henrik S Olsen, Ravi Vyzasatya, et al.Annals of the Rheumatic Diseases|April 15, 2004
A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexateS B Cohen, L W Moreland, J J Cush, et al.Melanoma Research|August 29, 2024
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital settingRonen Stoff, Svetomir N Markovic, Robert R McWilliams, et al.Oncoimmunology|June 12, 2020
HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancerYingxue Ren, Yesesri Cherukuri, Daniel P Wickland, et al.Gynecologic Oncology|May 3, 2017
Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancersGerardo Colon-Otero, S John Weroha, Nathan R Foster, et al.JCO Clinical Cancer Informatics|April 30, 2024
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language ProcessingHannah Barman, Sriram Venkateswaran, Antonio Del Santo, et al.Journal of Autoimmunity|August 24, 2017
Recombinant human IgG1 based Fc multimers, with limited FcR binding capacity, can effectively inhibit complement-mediated diseaseHaoping Sun, Henrik S Olsen, Emmanuel Y Mérigeon, et al.Oncogene|August 7, 2023
PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interactionUpasana Ray, Prabhu Thirusangu, Ling Jin, et al.Pageof 42